NR3C2 and chronic kidney disease: While recommended, the use of steroidal mineralocorticoid receptor antagonists (MRA) for patients with CKD and heart failure is often limited due to concerns of hyperkalemia, gynecomastia, impotence, and menstrual disturbances.